Skip to content
MedsAcross

Fixed-dose combination

Aspirin, Caffeine and Orphenadrine

Also known as aspirin, caffeine, orphenadrine citrate
Available on request
Presentations
5
Brands
3
Manufacturers
2
Available from stock
0

Aspirin, Caffeine and Orphenadrine is a fixed-dose combination of a central nervous system stimulant, a methylxanthine and a muscle relaxant indicated to moderate pain of acute musculoskeletal disorders. MedsAcross supplies Aspirin, Caffeine and Orphenadrine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Anti-Inflammatory Agents, Central Nervous System Stimulant, Methylxanthine, Muscle Relaxant, Nonsteroidal Anti-inflammatory Drug, Platelet Aggregation Inhibitor, Cyclooxygenase Inhibitors, Central Nervous System Stimulation, Centrally-mediated Muscle Relaxation, Decreased Platelet Aggregation, Decreased Prostaglandin Production
US FDA first approval
4 March 1964
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Tablet
Fixed-dose combination of
Aspirin, Caffeine, Orphenadrine

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Norgesic TM (orphenadrine citrate, aspirin and caffeine 25 mg/ 385 mg/ 30 mg) Tablets are indicated in: Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Norgesic TM Tablets do not directly relax tense muscles in man.

Source: US FDA prescribing information

Contraindications

Because of the mild anticholinergic effect of orphenadrine, Norgesic TM Tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy or obstructions at the bladder neck. Norgesic TM Tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. The drug is contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

Source: US FDA prescribing information

Warnings and precautions

Reye’s Syndrome may develop in individuals who have chicken pox, influenza, or flu symptoms. Some studies suggest possible association between the development of Reye’s Syndrome and the use of medicines containing salicylate or aspirin. Norgesic TM Tablets contain aspirin and therefore are not recommended for use in patients with chicken pox, influenza, or flu symptoms. Norgesic TM Tablets may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle, ambulatory patients should therefore be cautioned accordingly. Aspirin should be used with extreme caution in the presence of peptic ulcers and coagulation abnormalities.

Source: US FDA prescribing information

Side effects

Side effects of Norgesic TM Tablets are those seen with aspirin and caffeine or those usually associated with mild anti-cholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, and rarely, urticaria and other dermatosis. Infrequently, an elderly patient may experience some degree of confusion. Mild central excitation and occasional hallucinations may be observed. These mild side effects can usually be eliminated by reduction in dosage. One case of aplastic anemia associated with the use of orphenadrine citrate, aspirin and caffeine has been reported. No causal relationship has been established.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

5 presentations of Aspirin, Caffeine and Orphenadrine, sorted by availability.

MedicineActive ingredientManufacturerRegisterAvailability
Aspirin, Caffeine and Orphenadrine 385 mg/30 mg/25 mg tabletOralGeneric nameAspirin, Caffeine and Orphenadrine—US FDAAvailable on request
Aspirin, Caffeine and Orphenadrine 770 mg/60 mg/50 mg tabletOralGeneric nameAspirin, Caffeine and Orphenadrine—US FDAAvailable on request
Norgesic 385 mg/30 mg/25 mg tabletOralAspirin, Caffeine and OrphenadrineGalt PharmaceuticalsUS FDAAvailable on request
Norgesic Forte 770 mg/60 mg/50 mg tabletOralAspirin, Caffeine and OrphenadrinePoly PharmaceuticalsUS FDAAvailable on request
Orphengesic Forte 770 mg/60 mg/50 mg tabletOralAspirin, Caffeine and OrphenadrineGalt PharmaceuticalsUS FDAAvailable on request

Brands by market

3 brand names across 1 markets.

Brand names by country

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 4 March 1964Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Aspirin, Caffeine and Orphenadrine available for export from India?

Yes, on request. MedsAcross lists 5 presentations of Aspirin, Caffeine and Orphenadrine and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Aspirin, Caffeine and Orphenadrine have?

The catalogue lists 3 brand names for Aspirin, Caffeine and Orphenadrine, including Norgesic, Norgesic Forte, Orphengesic Forte.

Is Aspirin, Caffeine and Orphenadrine approved by the US FDA?

Yes. The US FDA first approved Aspirin, Caffeine and Orphenadrine on 4 March 1964, according to Drugs@FDA.

Does Aspirin, Caffeine and Orphenadrine need cold chain shipping?

No listed presentation of Aspirin, Caffeine and Orphenadrine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

References

  1. Norgesic prescribing information (Galt Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 8 January 2026

Request Aspirin, Caffeine and Orphenadrine for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.